Total submissions: 12
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000086167 | SCV000704550 | pathogenic | not provided | 2017-02-04 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000086167 | SCV001212418 | pathogenic | not provided | 2024-01-23 | criteria provided, single submitter | clinical testing | This sequence change replaces alanine, which is neutral and non-polar, with valine, which is neutral and non-polar, at codon 243 of the BEST1 protein (p.Ala243Val). The frequency data for this variant in the population databases is considered unreliable, as metrics indicate poor data quality at this position in the gnomAD database. This missense change has been observed in individuals with autosomal dominant macular dystrophy (PMID: 10854112, 28225368, 28559085). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 2737). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt BEST1 protein function with a positive predictive value of 95%. Experimental studies are conflicting or provide insufficient evidence to determine the effect of this variant on BEST1 function (PMID: 17065513, 24560797). For these reasons, this variant has been classified as Pathogenic. |
Blueprint Genetics | RCV001075633 | SCV001241260 | pathogenic | Retinal dystrophy | 2019-02-11 | criteria provided, single submitter | clinical testing | |
Ce |
RCV000086167 | SCV001245802 | pathogenic | not provided | 2024-04-01 | criteria provided, single submitter | clinical testing | BEST1: PP1:Strong, PM2, PM5, PS4:Moderate, PS3:Supporting |
Institute of Medical Genetics and Applied Genomics, |
RCV000086167 | SCV001446682 | pathogenic | not provided | 2020-10-23 | criteria provided, single submitter | clinical testing | |
Institute of Medical Molecular Genetics, |
RCV000002858 | SCV001548129 | likely pathogenic | Vitelliform macular dystrophy 2 | 2021-01-30 | criteria provided, single submitter | clinical testing | |
MGZ Medical Genetics Center | RCV000002858 | SCV002581427 | likely pathogenic | Vitelliform macular dystrophy 2 | 2022-03-03 | criteria provided, single submitter | clinical testing | |
Institute of Human Genetics, |
RCV003326112 | SCV004032306 | pathogenic | Autosomal dominant vitreoretinochoroidopathy | 2023-08-21 | criteria provided, single submitter | clinical testing | Criteria applied: PM5_STR,PS3_MOD,PS4_MOD,PM1,PM2_SUP,PP3 |
Institute of Human Genetics, |
RCV003448243 | SCV004175991 | pathogenic | Vitelliform macular dystrophy 1 | 2023-11-29 | criteria provided, single submitter | clinical testing | Criteria applied: PS4,PM5_STR,PS3_MOD,PM1,PM2_SUP |
OMIM | RCV000002858 | SCV000023016 | pathogenic | Vitelliform macular dystrophy 2 | 2000-04-01 | no assertion criteria provided | literature only | |
Retina International | RCV000086167 | SCV000118311 | not provided | not provided | no assertion provided | not provided | ||
Department of Clinical Genetics, |
RCV000002858 | SCV000926520 | likely pathogenic | Vitelliform macular dystrophy 2 | 2018-04-01 | no assertion criteria provided | research |